Adavosertib inhibited the growth of a Palbociclib-resistant PDX model of metastatic Erα+  CCND1-driven breast cancer by 70% after 60 days of treatment in Swiss nude mice in vivo. This evidence concerns the gene CCND1 and breast carcinoma.